The ROS/TXNIP/NLRP3 pathway mediates LPS-induced microglial inflammatory response

Qianlei Zhao1, Guanhao Liu2, Qiang Ding2

  • 1Department of Pediatric Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, PR China.

Cytokine
|June 19, 2024
PubMed
Abstract

Insights

Sepsis-associated encephalopathy involves microglia activation. This study shows N-acetyl-L-cysteine (NAC) inhibits the ROS/TXNIP/NLRP3 pathway, reducing inflammation in microglia during sepsis.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Sepsis-associated encephalopathy (SAE) is a complex brain dysfunction initiated by microglia.
  • The precise cellular mechanisms underlying SAE pathogenesis remain incompletely understood.
  • This research investigates the role of the ROS/TXNIP/NLRP3 pathway in lipopolysaccharide (LPS)-induced microglial activation.

Purpose of the Study:

  • To elucidate the involvement of the reactive oxygen species (ROS)/thioredoxin-interacting protein (TXNIP)/NLRP3 inflammasome pathway in LPS-induced microglial inflammatory responses.
  • To evaluate the therapeutic potential of N-acetyl-L-cysteine (NAC) in modulating this pathway.

Main Methods:

  • BV-2 microglial cells were treated with LPS and NAC.
  • Western blot analysis was used to assess protein expression levels of key inflammatory markers and pathway components (IBA1, CD68, TXNIP, NLRP3, ASC, Cleaved Caspase-1).
  • Enzyme-linked immunosorbent assay (ELISA) quantified inflammatory cytokine levels, and co-immunoprecipitation examined TXNIP-NLRP3 interactions.

Main Results:

  • LPS treatment increased microglial activation markers (IBA1, CD68), ROS production, and NLRP3 inflammasome activation.
  • NAC treatment partially reversed LPS-induced increases in ROS, inflammatory cytokines (IL-1β, IL-18), TXNIP, NLRP3, ASC, and Cleaved Caspase-1.
  • NAC also attenuated the interaction between TXNIP and NLRP3.

Conclusions:

  • Reactive oxygen species (ROS) inhibition is a key mechanism by which NAC inactivates the NLRP3 inflammasome signaling pathway.
  • Decreased TXNIP expression is central to ROS inhibition-mediated NLRP3 inflammasome inactivation.
  • Targeting the ROS/TXNIP/NLRP3 pathway presents a potential therapeutic strategy for SAE.